Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021

Lottenberg A, Nunes V, Nakandakare E, Neves M, Bernik M, Lagrost L . The human cholesteryl ester transfer protein I405V polymorphism is associated with plasma cholesterol concentration and its reduction by dietary phytosterol esters. J Nutr. 2003; 133(6):1800-5. DOI: 10.1093/jn/133.6.1800. View

Schwartz G, Bessac L, Berdan L, Bhatt D, Bittner V, Diaz R . Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168(5):682-9. DOI: 10.1016/j.ahj.2014.07.028. View

Han S, Leka L, Lichtenstein A, Ausman L, Schaefer E, Meydani S . Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res. 2002; 43(3):445-52. View

Brinton E, Mason R . Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids Health Dis. 2017; 16(1):23. PMC: 5282870. DOI: 10.1186/s12944-017-0415-8. View

Neil H, Hammond T, Huxley R, Matthews D, Humphries S . Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000; 321(7254):148. PMC: 27432. DOI: 10.1136/bmj.321.7254.148. View

Hu P, Dharmayat K, Stevens C, Sharabiani M, Jones R, Watts G . Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation. 2020; 141(22):1742-1759. DOI: 10.1161/CIRCULATIONAHA.119.044795. View

Ambrosetti M, Malfatto G, Maria Cremona A, Arca M, Faggiano P . [Familial hypercholesterolemia in cardiac rehabilitation: a new field of interest]. Monaldi Arch Chest Dis. 2015; 82(2):87-92. DOI: 10.4081/monaldi.2014.49. View

Catov J, Bodnar L, Kip K, Hubel C, Ness R, Harger G . Early pregnancy lipid concentrations and spontaneous preterm birth. Am J Obstet Gynecol. 2007; 197(6):610.e1-7. DOI: 10.1016/j.ajog.2007.04.024. View

Rader D, Kastelein J . Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014; 129(9):1022-32. DOI: 10.1161/CIRCULATIONAHA.113.001292. View

10.

Hooper L, Martin N, Abdelhamid A, Davey Smith G . Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2015; (6):CD011737. DOI: 10.1002/14651858.CD011737. View

11.

Buchwald H, VARCO R, Matts J, Long J, Fitch L, Campbell G . Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990; 323(14):946-55. DOI: 10.1056/NEJM199010043231404. View

12.

Odden M, Pletcher M, Coxson P, Thekkethala D, Guzman D, Heller D . Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Intern Med. 2015; 162(8):533-41. PMC: 4476404. DOI: 10.7326/M14-1430. View

13.

Miname M, Bittencourt M, Nasir K, Santos R . Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment. Curr Opin Lipidol. 2019; 30(2):82-87. DOI: 10.1097/MOL.0000000000000573. View

14.

Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A . Lipid-related markers and cardiovascular disease prediction. JAMA. 2012; 307(23):2499-506. PMC: 4211641. DOI: 10.1001/jama.2012.6571. View

15.

Ridker P, Rose L, Kastelein J, Santos R, Wei C, Revkin J . Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab. J Clin Lipidol. 2018; 12(4):958-965. DOI: 10.1016/j.jacl.2018.03.088. View

16.

Cannon C, Cariou B, Blom D, McKenney J, Lorenzato C, Pordy R . Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015; 36(19):1186-94. PMC: 4430683. DOI: 10.1093/eurheartj/ehv028. View

17.

Jansen A, van Aalst-Cohen E, Tanck M, Trip M, Lansberg P, Liem A . The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004; 256(6):482-90. DOI: 10.1111/j.1365-2796.2004.01405.x. View

18.

Narverud I, Retterstol K, Iversen P, Halvorsen B, Ueland T, Ulven S . Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis. 2014; 235(2):299-309. DOI: 10.1016/j.atherosclerosis.2014.05.917. View

19.

Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y . Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 1992; 95(1):1-13. DOI: 10.1016/0021-9150(92)90170-l. View

20.

Wang Q, Afshin A, Yakoob M, Singh G, Rehm C, Khatibzadeh S . Impact of Nonoptimal Intakes of Saturated, Polyunsaturated, and Trans Fat on Global Burdens of Coronary Heart Disease. J Am Heart Assoc. 2016; 5(1). PMC: 4859401. DOI: 10.1161/JAHA.115.002891. View